Glaxosmithkline Share Price | |
---|---|
Price | 1,647.00 |
Bid | 1,647.00 |
Ask | 1,647.50 |
Change | 7.50 (0.46%) |
Volume | 885,338 |
Open | 1,650.50 |
High | 1,656.00 |
Low | 1,644.50 |
Prev. Close | 1,639.50 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 4.09b |
Market Capitalisation | £67.30b |
Market Size | 1,500 |
52 Week High | 1,719.80 |
52 Week High Date | 07-Mar-2024 |
52 Week Low | 1,302.60 |
52 Week Low Date | 11-Jul-2023 |
# Trades | 2,408 |
---|---|
Vol. Sold | 385,616 |
Sold Value | £6.36m |
Vol. Bought | 400,558 |
Bought Value | £6.61m |
PE Ratio | 13.54441 |
Earnings | 121.60 |
Dividend | 55.50 |
Yield | 3.37% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
23-Apr-24 | 12:33:48 | 1,647.00 | 500 | Sell* | 1,647.00 | 1,647.50 | 8,235 | O Ordinary Trade was executed as an SI |
23-Apr-24 | 12:33:28 | 1,647.50 | 0 | Unknown* | 1,647.00 | 1,647.50 | 0.00 | O Ordinary Trade was executed as an SI |
23-Apr-24 | 12:33:07 | 1,647.00 | 83 | Buy* | 1,646.50 | 1,647.00 | 1,367 | A Automatic Execution |
23-Apr-24 | 12:33:07 | 1,647.00 | 63 | Buy* | 1,646.50 | 1,647.00 | 1,038 | A Automatic Execution |
23-Apr-24 | 12:33:07 | 1,647.00 | 84 | Buy* | 1,646.50 | 1,647.00 | 1,383 | A Automatic Execution |
23-Apr-24 | 12:33:07 | 1,647.00 | 354 | Buy* | 1,646.50 | 1,647.00 | 5,830 | A Automatic Execution |
23-Apr-24 | 12:32:59 | 1,646.68 | 6 | Buy* | 1,646.00 | 1,647.00 | 98.80 | O Ordinary |
23-Apr-24 | 12:32:50 | 1,646.5904 | 361 | Buy* | 1,646.00 | 1,647.00 | 5,944 | O Ordinary |
23-Apr-24 | 12:32:36 | 1,646.50 | 545 | Unknown* | 1,646.00 | 1,647.00 | 8,973 | O Ordinary |
23-Apr-24 | 12:32:16 | 1,646.50 | 260 | Sell* | 1,646.00 | 1,647.00 | 4,281 | A Automatic Execution |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
19-Apr-24 | 16-Apr-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 39.79 | USD | 2,906,213 | 3,370,704 |
19-Apr-24 | 16-Apr-24 | Buy Dividends | Emma Walmsley held the position of CEO at the time of this trade.Emma Walmsley | 1,611.28 | GBX | 1,840,922 | 2,190,842 |
15-Apr-24 | 12-Apr-24 | Buy Dividends | Anne Beal held the position of Independent Non-Executive Director at the time of this trade.Anne Beal | 40.96 | USD | 9 | 3,375 |
15-Apr-24 | 12-Apr-24 | Buy Dividends | Harry (Hal) C. Dietz held the position of Independent Non-Executive Director at the time of this trade.Harry (Hal) C. Dietz | 40.96 | USD | 9 | 3,118 |
15-Apr-24 | 12-Apr-24 | Buy Dividends | Hal Barron held the position of Non-Executive Director at the time of this trade.Hal Barron | 40.96 | USD | 13 | 464,491 |
At GSK, we unite science, technology and talent to get ahead of disease together